

Sen. Cristina Castro

## Filed: 3/1/2019

	10100SB1909sam001	LRB101 09278 KTG 56901 a
1	AMENDMENT TO SENA	TE BILL 1909
2	AMENDMENT NO Amend Se	enate Bill 1909 on page 3, by
3	replacing line 16 with the following:	
4	"by adding Sections 10-23 and 10-24 as follows:	
5	(20 ILCS 1305/10-23 new)	
6	<u>Sec. 10-23. High Risk Infa</u>	ant Follow-Up program. The
7	Department's High Risk Infant Follow-Up program shall be	
8	expanded to serve any pregnant or postpartum woman identified	
9	as high-risk by a Level I, Level I	I, or Level III hospital. The
10	services shall be provided by registered nurses.	
11	The Department, in conjunct:	ion with the Department of
12	Public Health, a statewide	organization representing
13	registered nurses, and a statewide organization representing	
14	obstetricians and gynecologists,	, shall develop rules and
15	appropriate revisions to the High N	Risk Infant Follow-Up program
16	to expand existing services provi	ded by registered nurses to

10100SB1909sam001 -2- LRB101 09278 KTG 56901 a

## 1 pregnant and postpartum women. Such rules shall be adopted no later than January 1, 2021."; and 2 3 on page 77, immediately below line 22, by inserting the 4 following: "Section 57. The Medical Patient Rights Act is amended by 5 6 changing Section 3 as follows: 7 (410 ILCS 50/3) (from Ch. 111 1/2, par. 5403) 8 Sec. 3. The following rights are hereby established: (a) The right of each patient to care consistent with sound 9 10 nursing and medical practices, to be informed of the name of the physician responsible for coordinating his or her care, to 11 12 receive information concerning his or her condition and 13 proposed treatment, to refuse any treatment to the extent permitted by law, and to privacy and confidentiality of records 14 15 except as otherwise provided by law. (b) The right of each patient, regardless of source of 16 17 payment, to examine and receive a reasonable explanation of his total bill for services rendered by his physician or health 18 care provider, including the itemized charges for specific 19 20 services received. Each physician or health care provider shall

21 be responsible only for a reasonable explanation of those 22 specific services provided by such physician or health care 23 provider. 10100SB1909sam001 -3- LRB101 09278 KTG 56901 a

1 (c) In the event an insurance company or health services 2 corporation cancels or refuses to renew an individual policy or 3 plan, the insured patient shall be entitled to timely, prior 4 notice of the termination of such policy or plan.

5 An insurance company or health services corporation that requires any insured patient or applicant for new or continued 6 insurance or coverage to be tested for infection with human 7 8 immunodeficiency virus (HIV) or any other identified causative agent of acquired immunodeficiency syndrome (AIDS) shall (1) 9 10 give the patient or applicant prior written notice of such 11 requirement, (2) proceed with such testing only upon the written authorization of the applicant or patient, and (3) keep 12 the results of such testing confidential. Notice of an adverse 13 14 underwriting or coverage decision may be given to any 15 appropriately interested party, but the insurer may only 16 disclose the test result itself to a physician designated by the applicant or patient, and any such disclosure shall be in a 17 manner that assures confidentiality. 18

19 The Department of Insurance shall enforce the provisions of 20 this subsection.

21 The right of each patient to privacy (d) and confidentiality in health care. Each physician, health care 22 23 provider, health services corporation and insurance company 24 shall refrain from disclosing the nature or details of services 25 provided to patients, except that such information may be 26 disclosed: (1) to the patient, (2) to the party making 10100SB1909sam001 -4- LRB101 09278 KTG 56901 a

1 treatment decisions if the patient is incapable of making decisions regarding the health services provided, (3) 2 for treatment in accordance with 45 CFR 164.501 and 164.506, (4) 3 4 for payment in accordance with 45 CFR 164.501 and 164.506, (5) 5 to those parties responsible for peer review, utilization review, and quality assurance, (6) for health care operations 6 in accordance with 45 CFR 164.501 and 164.506, (7) to those 7 8 parties required to be notified under the Abused and Neglected 9 Child Reporting Act or the Illinois Sexually Transmissible 10 Disease Control Act, or (8) as otherwise permitted, authorized, 11 or required by State or federal law. This right may be waived in writing by the patient or the patient's guardian or legal 12 13 representative, but a physician or other health care provider may not condition the provision of services on the patient's, 14 15 quardian's, or legal representative's agreement to sign such a 16 waiver. In the interest of public health, safety, and welfare, patient information, including, but not limited to, health 17 information, demographic information, and information about 18 the services provided to patients, may be transmitted to or 19 20 through a health information exchange, as that term is defined 2 of the Mental Health and Developmental 21 in Section Disabilities Confidentiality Act, in accordance with the 22 23 disclosures permitted pursuant to this Section. Patients shall 24 be provided the opportunity to opt out of their health 25 information being transmitted to or through а health 26 information exchange in accordance with the regulations,

10100SB1909sam001 -5- LRB101 09278 KTG 56901 a

standards, or contractual obligations adopted by the Illinois 1 Health Information Exchange Authority in accordance with 2 3 Section 9.6 of the Mental Health and Developmental Disabilities 4 Confidentiality Act, Section 9.6 of the AIDS Confidentiality 5 Act, or Section 31.8 of the Genetic Information Privacy Act, as applicable. In the case of a patient choosing to opt out of 6 having his or her information available on an HIE, nothing in 7 8 this Act shall cause the physician or health care provider to 9 be liable for the release of a patient's health information by 10 other entities that may possess such information, including, 11 but not limited to, other health professionals, providers, laboratories, pharmacies, hospitals, ambulatory surgical 12 13 centers, and nursing homes.

14 (e) With the exception of medical emergencies with 15 inadequate time to obtain consent, the right of each patient, 16 or patient's representative, to specific informed consent, or informed permission in the case of an infant, including 17 information regarding the health and legal benefits and risks 18 19 regarding biochemical testing for controlled substances. 20 Health care providers shall provide to patients, or patients' representatives, in writing, the following: 21

(1) foreseeable health and legal risks and benefits of
biochemical testing for controlled substances;
(2) reasonable alternatives to biochemical testing for
controlled substances;

26 (3) information on how to obtain answers to questions

10100SB1909sam001

1	about substance abuse treatment;
2	(4) information on the applicability of federal safe
3	harbor protections; and
4	(5) an explanation of the extent of confidentiality and
5	the voluntariness of agreement to biochemical testing for
6	controlled substances.
7	(Source: P.A. 98-1046, eff. 1-1-15.)".